Vivas Alejandra, Escandon Julia, Lebrun Elizabeth, Choudhary Sonal, Tang Jennifer, Kirsner Robert S
Department of Dermatology & Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA.
Surg Technol Int. 2010 Oct;20:83-96.
Diabetic foot ulcers are a common problem in clinical practice and one of the most common complications in diabetic patients, often leading to amputation and hospitalization. Although there are a number of options for coadjuvant therapy for diabetic foot ulcers, a considerable number of patients remain unhealed after 12 weeks of treatment and, in general, rates of healing remain low. For these reasons, as well as the rising costs of associated complications of nonhealing diabetic foot ulcers, there is an impetus for the research community to develop more sophisticated ways to manage this condition. We reviewed ongoing clinical trials (clinicaltrials.gov) testing new therapies for foot ulcers and searched the basic science literature for preclinical background of these products. We focused our review on new therapies that include topicals, skin substitutes, bioengineered skin, cellular therapy growth factors, devices, and herbal medications. All of these options are analyzed and presented in this review as promising new options for the treatment of diabetic foot ulcers.
糖尿病足溃疡是临床实践中的常见问题,也是糖尿病患者最常见的并发症之一,常导致截肢和住院。尽管糖尿病足溃疡有多种辅助治疗选择,但相当一部分患者在治疗12周后仍未愈合,总体而言,愈合率仍然较低。由于这些原因,以及未愈合的糖尿病足溃疡相关并发症成本的不断上升,研究界有动力开发更先进的方法来管理这种疾病。我们回顾了正在进行的测试足部溃疡新疗法的临床试验(clinicaltrials.gov),并在基础科学文献中搜索了这些产品的临床前背景。我们的综述重点关注包括局部用药、皮肤替代物、生物工程皮肤、细胞治疗生长因子、器械和草药在内的新疗法。本综述分析并介绍了所有这些选择,认为它们是治疗糖尿病足溃疡的有前景的新选择。